Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.
Wiklund has lots of experience in Pharmaceutical and Biotechnology Industries. He was also a cofounder of Esperion Therapeutics, which was sold for $1,3 Billion to Pfizer. Regardles of him creating a company interesting to pharma giants, Xbrane will welcome his expertize for outlucensing of prostate cancer drug Spherotide, generic of the drug marketed under the names Decapeptyl/Trelstar/Pamorelin, and eye disease drug Xlucane, a biosimilar candidate to Roche’s Lucentis.
“We are very excited to have Anders P. Wiklund as a strategic advisor to Xbrane. His long experience in M&A and licensing in the Pharmaceutical sector will be of great value for Xbrane in the upcoming out-licensing of both Spherotide and Xlucane”, says Martin Åmark, Xbranes CEO.
“I am impressed both by the entrepreneurial spirit at Xbrane and its innovative, patented technology that has the promise of making the company a very important player in the Biosimilar space. I look forward with enthusiasm to work with the management of Xbrane, in this exciting phase of the company development, particularly regarding the global expansion and out-licensing of Xbranes leading products.” said Anders P. Wiklund.